Bright minds biosciences announces positive topline data for its first-in-human phase 1 study of lead compound, bmb-101

-- bmb-101 is a highly selective and potent 5-ht2c agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders

DRUG Ratings Summary

DRUG Quant Ranking